2021 Fiscal Year Final Research Report
Morphological and molecular biological research aimed at personalized medicine of patients with salivary duct carcinoma
Project/Area Number |
19K16568
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 49020:Human pathology-related
|
Research Institution | Tokyo Medical University |
Principal Investigator |
Hirai Hideaki 東京医科大学, 医学部, 助教 (00770744)
|
Project Period (FY) |
2019-04-01 – 2022-03-31
|
Keywords | 唾液腺導管癌 / androgen receptor (AR) / HER2 / PD-1 / PD-L1 / EZH2 / adipophilin / FASN |
Outline of Final Research Achievements |
In this study, we analyzed salivary duct carcinoma (SDC) cases including patient treated with HER2- or AR-targeted therapy, and investigated predictive factors of these therapies and tumor immune microenvironment. A high expression of EZH2 in SDC was a predictor of a poor efficacy of AR-targeted therapy. A high expression of adipophilin, lipid metabolism-related protein, was associated with an aggressive histopathology and unfavorable prognosis. Furthermore, in tumor immune microenvironment, SDC cases with high PD-L1 expression showed aggressive histological features and a poor prognosis.
|
Free Research Field |
人体病理学
|
Academic Significance and Societal Importance of the Research Achievements |
今回の研究で唾液腺導管癌(SDC)の予後因子や治療効果予測因子の一部が明らかになったことは、高悪性度腫瘍でかつ標準治療が確立していないSDCの治療戦略構築の一助になるものと考えられる。また、免疫微小環境のうちPD-1とPD-L1の臨床病理学的意義を明らかにしたことは、PD-1阻害薬をはじめとする免疫療法をSDCの治療に導入するにあたって有意義な基礎的データとなるであろう。
|